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Angiotensin receptor blockers (ARBs) are the ﬁrst-line antihypertensive agents.  In clinical practice,  it 
is often diﬃcult to achieve the recommended blood pressure level by ARBs in their ordinal dosages 
alone.  This study examined the practical eﬃcacy of a combination therapy of ARB with thiazide 
diuretics for lowering morning home blood pressure (MHBP) in comparison to high-dose ARB therapy 
in patients with morning hypertension administered an ordinal dosage of ARB.  This study was per-
formed in a prospective,  randomized,  open-labeled and blind-endpoint fashion.  Patients were consid-
ered to have morning hypertension when their self-measured systolic MHBPs were 135mmHg or 
higher,  irrespective of their diastolic MHBP and oﬃce blood pressures (OBPs).  Forty-eight outpa-
tients with morning hypertension receiving the ordinal dosage of ARB were given either losartan/
hydrochlorothiazide (n＝26) or high-dose ARB (n＝22) in place of their previously prescribed ARB.  No 
change in any medication was permitted during this period.  Decreases of both systolic and diastolic 
MHBP after 3 months of treatment were signiﬁcantly greater in the losartan/hydrochlorothiazide 
group than in the high-dose ARB group (p＜0.05,  respectively).  The ratio of adverse events was some-
what high (23.1ｵ in the losartan/hydrochlorothiazide group,  9.1ｵ in the high-dose ARB group,  
respectively).  However,  there were no signiﬁcant diﬀerences in any particular adverse event between 
groups.  This study suggested losartan/hydrochlorothiazide might be superior to high-dose ARB for 
reducing morning home blood pressure.
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ypertension is a risk factor for mortality and 
morbidity by cardiovascular diseases [1-4],  
and thus reduction of blood pressure is very important 
to reduce cardiovascular diseases-associated mortality 
and morbidity [5-8].  Angiotensin receptor blockers 
(ARBs) are the ﬁrst-line antihypertensive agents.  
However,  hypertensive patients treated with a single 
antihypertensive agent often fail to achieve the target 
blood pressure level,  and thus most hypertensive 
patients need 2 or more antihypertensive agents [9,  
10].  Consequently,  many guidelines have discussed 
which combinations of antihypertensive agents are 
most favorable [5,  9,  10].  The ARB/thiazide combi-
nation therapy has been highlighted,  in part because 
ARBs counterbalance the hypokalemia induced by 
thiazide diuretics.  Another reason for the favorability 
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of this combination is that the natriuretic action of 
thiazide diuretics increases rennin-angiotensin system 
(RAS) activity,  which in turn enhances the eﬃcacy of 
RAS inhibitors.  Indeed,  several studies have reported 
the eﬃcacy of ARB/thiazide combination therapy for 
reducing blood pressure in uncontrolled hypertensive 
patients [11].  On the other hand,  high-dose ARB 
therapy is also important.  In order to inhibit not only 
systemic RAS activity but also local RAS activity,  
high-dose ARB therapy is required in some cases.  
Studies have reported that high-dose ARBs conferred 
eﬀective organ protection [12,  13].
　 Elevated morning home blood pressure (MHBP) is 
a causative factor of mortality and morbidity by car-
diovascular disease [14-17].  Although it remains 
unclear whether a reduction of MHBP can improve the 
mortality and morbidity by cardiovascular disease,  it 
is reasonable to consider that the management of 
MHBP is as important as that of casual BP.  Indeed,  
many clinicians use MHBP as an index of the eﬃcacy 
of hypertension treatment in clinical practice.  However,  
no clear guidelines have been published for the man-
agement of MHBP.
　 We hypothesized that ARB/thiazide combination 
therapy would be superior for reducing MHBP com-
pared to high-dose ARB therapy in hypertensive 
patients treated with an ordinal dosage of ARB.  In the 
present study,  therefore,  we compared the practical 
eﬃcacy of ARB/thiazide combination therapy to that 
of high-dose ARB therapy in reducing MHBP in 
patients with morning hypertension.
Materials and Methods
　 Study objective. The objective of this study 
was to compare the levels of MHBP reduction between 
combination therapy with losartan/hydrochlorothiaz-
ide (HCTZ) and high-dose ARB therapy in patients 
with morning hypertension.  Morning hypertension was 
deﬁned as systolic MHBP of 135mmHg or over.  The 
primary endpoints were decreases of systolic and 
diastolic MHBP.  The secondary endpoints were 
decreases of systolic and diastolic oﬃce blood pres-
sure (OBP).
　 Subjects. Participants were recruited between 
January 2008 and March 2010.  We enrolled outpa-
tients with hypertension who were administered an 
ordinal dosage of ARBs and whose average systolic 
MHBPs were 135mmHg or over (Table 1).
　 Patients who met any of the following criteria were 
excluded: inability to perform self-blood pressure 
measurement; age under 20 years or over 80 years;  
severe hypertension (diastolic MHBP 120mmHg or 
over); severe diabetes mellitus (hemoglobin A1c 
(HbA1c) level over 8.0ｵ); acute myocardial infarction,  
stroke or other vascular disease over the preceding 3 
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Table 1　 Inclusion and exclusion criteria
Inclusion Criteria
　Age of 20 to 79 years
　Ability to perform self-blood pressure measurement at home
　Outpatient status
　Morning home systolic blood pressures of 135mmHg or over
　Provision of informed consent
Exclusion Criteria
　Uncontrolled blood pressures: diastolic morning home blood pressure of 120mmHg or over
　Diabetes mellitus with uncontrolled plasma glucose levels: hemoglobin A1c of 8.0% or over
　Acute myocardial infarction,  stroke or other vascular disease within 3 months
　Heart failure of New York Heart Association functional class III or IV
　Gout or hyperuricemia: serum uric acid level of 8.0mg/dl or over
　Renal failure: serum creatinine level of 2.0mg/dl or over
　Liver injury: aspartate aminotransferase or alanine aminotransferase level elevated to more than three times the upper limit of normal
　Bilateral renal arterial stenosis,  malignant hypertension or endocrine secondary hypertension
　Use of thiazide diuretics
　Pregnancy
　Disqualiﬁcation for other reasons at the discretion of the physician in charge
months; heart failure of New York Heart Association 
functional class III or IV; gout or serum uric acid 
(UA) level of 8.0mg/dl or over; renal failure (serum 
creatinine (Cr) level of 2.0mg/dl or over); liver 
injury (aspartate amino transferase (AST) or alanine 
transaminase (ALT) level 3 times higher than the 
upper limit of normal); bilateral renal arterial 
stenosis; malignant hypertension; secondary hyper-
tension; treatment with thiazide diuretics; pregnant;  
allergy to the drugs used in this study; and any other 
conditions rendering them inappropriate for participa-
tion based on the assessment of their attending physi-
cians.
　 Study design. This study was a multi-center (5 
hospitals and 5 clinics),  prospective,  randomized and 
open-labeled study with a 3-month,  2-arm parallel 
treatment group comparison and a ﬁxed-dose scheme 
(Fig.  1).  The patients were assigned to 1 of 2 groups,  
the Losartan/HCTZ group or the High-dose ARB 
group.  Patients in the Losartan/HCTZ group were 
administered losartan/HCTZ in place of the previ-
ously prescribed ARB,  while patients in the High-dose 
ARB group were administered the maximum dosage of 
previous ARBs approved in Japan: losartan,  
100mg; candesartan,  12mg; valsartan,  160mg; tel-
misartan,  80mg; olmesartan,  40mg; or irbesartan,  
200mg.  The sample size was determined on the basis 
of the estimated BP reduction reported in a recent 
study which showed the superiority of combination 
therapy with losartan 50mg plus HCTZ 12.5mg com-
pared to losartan 100mg after 8 weeks of treatment in 
reduction of systolic OBP (－16.8mmHg vs. －6.4mmHg,  
p＜0.01) [18].  We assumed that the mean reduction 
of systolic MHBP was 10.4mmHg and the standard 
deviation (SD) was 10.0mmHg.  For using a 2-sided 
test for diﬀerences,  a minimal sample size of 16 
patients was required in each group to detect statisti-
cal diﬀerences in reduction of systolic MHBP with a 
power of 80ｵ and an α-type error of 5ｵ in the sta-
tistical analysis.  The results are expressed as the 
means ± SD.
　 Blood pressure measurement. The method of 
self-blood pressure measurement followed the 
Japanese Society of Hypertension Guidelines for the 
Management of Hypertension (JSH 2009) [5].  In 
brief,  MHBP was measured using a cuﬀ-oscillometric 
automated sphygmomanometer within an hour after 
waking,  after urination,  before morning dosing,  before 
breakfast and after 1 to 2 min of rest in a sitting posi-
tion.  Blood pressure and pulse rate data were 
recorded on recording sheets and marked on a data 
sheet by the patients themselves.  The average levels 
of systolic and diastolic MHBP and morning pulse rate 
before the enrollment and 3 months after treatment 
were determined as the average values of all data 
within a month just before the enrollment and the last 
month,  respectively.
　 OBP measurement was conducted at every visit.  
OBP was measured in a sitting position using an 
automated sphygmomanometer or mercury column 
sphygmomanometer by each physician.
　 Parameters. Background medical information 
was obtained at the time of enrollment,  and included 
age,  gender,  body mass index (BMI),  past medical 
history (including information on ischemic heart dis-
ease,  stroke,  diabetes mellitus,  dyslipidemia and 
chronic kidney disease),  current smoking and current 
alcohol drinking.
　 Laboratory data,  AST,  ALT,  Cr,  estimated 
glomerular ﬁltration rate (eGFR),  UA,  potassium,  
HbA1c,  low density lipoprotein cholesterol (LDL-
Cho),  high density lipoprotein cholesterol (HDL-Cho) 
and triglyceride (TG) were examined before enroll-
ment and at the end of the study.  The eGFR of each 
participant was calculated using the Japanese eGFR 
equation recently determined by the Japanese Society 
of Nephrology: eGFR (ml/min/1.73m2)＝194×
age－0.287×Cr －1.094× (0.739 if female) [19].
　 Ethics. The study protocol was approved by the 
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Fig. 1　 Outline of this study.  Hypertensive patients whose morn-
ing home systolic blood pressure was 135mmHg or over with an 
ordinal dosage of ARB were enrolled.  They were assigned to two 
groups,  the Losartan/HCTZ group or the High-dose ARB group.  
Patients assigned to the Losartan/HCTZ group were administered 
losartan/hydrochlorothiazide (losartan/HCTZ),  while patients 
assigned to the High-dose ARB group were administered the maxi-
mum dosage of ARB approved in Japan: 100mg losartan; 12mg 
candesartan ; 160mg valsartan ; 80mg telmisartan ; 40mg 
olmesartan; 200mg irbesartan.
Okayama University Institutional Review Board 
(accredited ISO9001/2000) and by the local ethic 
committees at the respective institutes where avail-
able.  It was undertaken in accordance with the 
Declaration of Helsinki and the Ethical Guidelines for 
Clinical Studies in Japan.  All patients enrolled in this 
study provided fully informed written consent.  
Participants who suﬀered from adverse events were 
immediately excluded from this study and given the 
appropriate treatment and medical care.
　 Statistical analysis. Data are presented the 
mean ± standard deviation.  Numerical data qualiﬁed 
F-test and normality test were analyzed using 
Studentʼs t-test,  and other numerical data were ana-
lyzed using Mann-Whitneyʼs U-test.  Categorical data 
were analyzed using Fisherʼs exact probability test.  
The statistical analysis was performed using the sta-
tistical software packages,  Stat View 5.0 and 
SigmaStat 3.5 (SPSS Inc.).
Results
　 Enrollment. A total of 48 patients were 
enrolled.  Twenty-six patients were assigned to the 
Losartan/HCTZ group,  and 8 of those patients 
dropped out (Fig.  2).  Twenty-two patients were 
assigned to the High-dose ARB group,  and 5 patients 
dropped out.  Total of 35 patients thus completed the 
study.
　 Patient characteristics at baseline. Each 
parameter at baseline is shown in Table 2.  There 
were no statistically signiﬁcant diﬀerences in any of 
the parameters between the groups.
　 Morning home blood pressure. The decrease 
of systolic MHBP in the Losartan/HCTZ group was 
signiﬁcantly greater than that in the High-dose ARB 
group (16±5mmHg vs. 6±10mmHg,  p＝0.0217,  
Fig.  3A).  Both groups tended to have a gradually 
decreasing systolic MHBP level (Fig.  3C).  The ﬁnal 
systolic MHBP level 3 months after treatment in the 
Losartan/HCTZ group was signiﬁcantly lower than 
that in the High-dose ARB group (127±7mmHg vs. 
138±14mmHg,  p＝0.0416).  The decrease of dia-
stolic MHBP in the Losartan/HCTZ group was sig-
niﬁcantly greater than that in the High-dose ARB 
group (7.8±5.2mmHg vs. 2.9±4.4mmHg,  p＝0.0075,  
Fig.  3B).  There was no signiﬁcant diﬀerence between 
the diastolic MHBP level of the Losartan/HCTZ 
group and that of the High-dose ARB group either 
enrollment or after treatment (Fig.  3C).  The ratio of 
subjects with systolic MHBP under 135mmHg after 
treatment in the Losartan/HCTZ group was signiﬁ-
cantly higher than that in the High-dose ARB group 
(72ｵ vs. 35ｵ,  p＝0.0437).
　 Oﬃce blood pressure. There were no signiﬁ-
cant diﬀerences in the magnitude of decrease of sys-
tolic and diastolic OBP between the Losartan/HCTZ 
group and the High-dose ARB group (Fig.  4A and B).  
In addition,  there were no signiﬁcant diﬀerences 
between the Losartan/HCTZ group and the High-dose 
ARB group in the systolic or diastolic OBP level 
(Fig.  4C).
　 Changes of laboratory data. The changes of 
laboratory data between the baseline and after treat-
ment measurements were evaluated (Table 3).  The 
Change of Cr in the Losartan/HCTZ group was 
greater than that in the High-dose ARB group (0.06±
0.07mg/dl vs. 0.00±0.07mg/dl,  p＝0.0393).  However,  
there was no signiﬁcant diﬀerence in the changes of 
eGFR or serum potassium level in either group.  UA 
was elevated more in the Losartan/HCTZ group than 
in the High-dose ARB group (0.6±0.7mg/dl vs. 0.0 
±0.7mg/dl,  p＝0.0369).  In the Losartan/HCTZ 
group,  1 patient had hyperuricemia at baseline,  while 
452 Acta Med.  Okayama　Vol.  66,  No.  6Hanayama et al.
Enrollment 48
Losartan/HCTZ High-dose ARB
Complete
8 5
18 17
Dropouts
Brain hemorrhage 1
Hypotension 1
Headache 1
Chest discomfort 1
Eczema 2
Others 2
Dropouts
Hypotension with syncope 1
Others 4
26 22
Complete
Fig. 2　 Enrollment.  Forty-eight patients with morning hyperten-
sion were assigned to one of two groups,  the Losartan/HCTZ group 
or the High-dose ARB group.  Eight patients in the Losartan/HCTZ 
group dropped out due to brain hemorrhage,  hypotension,  head-
ache,  chest discomfort,  eczema or other reasons.  Five patients in 
the High-dose ARB group dropped out due to hypotension with 
syncope and other reasons.  A total of 18 and 17 patients thus 
completed the study in the Losartan/HCTZ group or the High-dose 
ARB group,  respectively.
3 patients were newly diagnosed with hyperuricemia 
after treatment.  On the other hand,  in the High-dose 
ARB group 3 patients had hyperuricemia at baseline,  
while none were newly diagnosed with hyperuricemia.  
There were no signiﬁcant diﬀerences in the other 
parameters between the 2 groups.
　 Adverse events. Adverse events are shown in 
Table 4.  The ratio of adverse events was 23.1ｵ in 
the Losartan/HCTZ group and 9.1ｵ in the High-dose 
ARB group.  These ratios were fairly high,  especially 
in the former group.  However,  there were no signiﬁ-
cant diﬀerences in any particular adverse event 
between groups (Table 4).  All patients recovered from 
these events after cessation of the causative drugs.  
One patient in the Losartan/HCTZ group had a brain 
hemorrhage 1 month after treatment.  Although she 
presented with dysarthria and paralysis in the right 
upper extremity at onset,  both symptoms were dimin-
ished 6 months later.
Discussion
　 This study compared the blood pressure-lowering 
eﬀect of losartan/HCTZ combination therapy to that 
of high-dose ARB therapy in patients who were 
treated with an ordinal dosage of ARB but had sys-
tolic MHBP of 135mmHg or over in clinical practice.  
The results demonstrated that losartan/HCTZ combi-
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Table 2　 Patientsʼ characteristics at baseline
Losartan/HCTZ group
(n＝26)
High-dose ARB group
(n＝22) P value
Age (years) 65±9 64±11 0.6342
Gender (male/female) 13/13 9/13 0.5729
BMI (kg/m2) 25.0±3.7 24.4±3.7 0.5708
Systolic MHBP (mmHg) 146±12 148±10 0.7142
Diastolic MHBP (mmHg) 87±9 81±10 0.0672
MHPR (beats per minute) 70±13 64±9 0.1394
Systolic OBP (mmHg) 141±17 139±17 0.6837
Diastolic OBP (mmHg) 80±12 77±11 0.3238
OPR (beats per minute) 65±11 69±9 0.3315
Cr (mg/dl) 0.81±0.24 0.79±0.22 0.7860
eGFR (ml/min/1.73m2) 67.6±14.5 67.8±13.9 0.9511
UA (mg/dl) 4.8±1.3 5.2±1.3 0.2889
K (mEq/l) 4.4±0.4 4.5±0.4 0.1705
HbA1c (%) 6.0±1.4 5.8±0.5 0.6970
LDL-Cho (mg/dl) 116±27 113±26 0.7068
HDL-Cho (mg/dl) 55±11 62±23 0.2961
TG (mg/dl) 162±102 126±60 0.3009
IHD (%) 4 0 0.9999
Stroke (%) 8 0 0.4929
Diabetes mellitus (%) 38 23 0.3506
Dyslipidemia (%) 50 41 0.5729
Hyperuricemia (%) 8 14 0.6492
CKD (%) 35 14 0.1797
Smoking (%) 20 0 0.0562
Habitual drinking (%) 24 15 0.7095
BMI,  body mass index; systolic MHBP,  morning home systolic blood pressure; diastolic MHBP,  morning home diastolic blood pressure;  
MHPR,  morning home pulse rate; systolic OBP,  oﬃce systolic blood pressure; diastolic OBP,  oﬃce diastolic blood pressure; OPR,  
oﬃce pulse rate; Cr,  creatinine; eGFR,  estimated glomerular ﬁltration rate; K,  potassium; UA,  uric acid; HbA1c,  hemoglobin A1c; LDL-
Cho,  low density lipoprotein cholesterol; HDL-Cho,  high density lipoprotein cholesterol; TG,  triglyceride; IHD,  ischemic heart 
disease; CKD,  chronic kidney disease.
P values were analyzed using Studentʼs t-test,  Mann-Whitneyʼs U-test or Fisherʼs exact probability test,  where appropriate.
nation therapy achieved a signiﬁcantly greater reduc-
tion in MHBP compared to high-dose ARB therapy.  
Furthermore,  losartan/HCTZ combination therapy 
was superior to high-dose ARB therapy in terms of the 
ratio of patients with systolic MHBP under 135mmHg.  
In this study,  the decreases of both systolic and dia-
stolic MHBP in patients receiving losartan/HCTZ 
combination therapy were signiﬁcantly greater than 
those in patients receiving the high-dose ARB therapy.
　 ARBs are recommended as the ﬁrst-line antihyper-
tensive agents for treatment of hypertension by JSH 
2009,  JNC-7 and ESH/ESC 2007 [5,  9,  10].  
However,  most hypertensive patients require 2 or 
more antihypertensive agents to achieve their target 
blood pressure [9,  10].  The importance of second-
line antihypertensive has raised the question of which 
combination therapies are most useful,  and the pres-
ent study was designed to examine this issue.  One 
possible strategy to address an inadequate blood pres-
sure decrease would be to increase of the dosage of 
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Fig. 4　 Decreases of oﬃce blood pressure.  The 
closed boxes and circules show the results for the 
Losartan/HCTZ group and the open boxes and cir-
cles show the results for the High-dose ARB group.  
Panel A shows the decrease of oﬃce systolic blood 
pressure,  and panel B shows the decrease of oﬃce 
diastolic blood pressure.  Decreases of both systolic 
and diastolic oﬃce blood pressure in the Losartan/
HCTZ group were not signiﬁcantly diﬀerent from those 
in the High-dose ARB group.  Panel C shows oﬃce 
blood pressure levels.  There was no signiﬁcant diﬀer-
ence in the oﬃce blood pressure levels between the 
two groups at enrollment and after treatment.  P val-
ues were calculated by Mann-Whitneyʼs U-test 
between both groups in panel A and B.  P values 
were calculated by unpaired t-test between both 
groups in panel C.
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Fig. 3　 Decreases of morning home blood pressure 
and morning home blood pressure levels.  The closed 
boxes and circles show the Losartan/HCTZ group and 
the open boxes and circles show the High-dose ARB 
group.  Panel A shows the decrease of morning home 
systolic blood pressure.  The decrease of morning 
home systolic blood pressure in the Losartan/HCTZ 
group was signiﬁcantly greater than that in the High-
dose ARB group.  Similarly,  panel B shows that the 
decrease of morning home diastolic blood pressure in 
the Losartan/HCTZ group was signiﬁcantly greater 
than that in the High-dose ARB group.  Panel C 
shows the morning home blood pressure levels.  The 
systolic morning home blood pressure level in the 
Losartan/HCTZ group was signiﬁcantly lower than 
that in the High-dose ARB group after treatment.  
There was no signiﬁcant diﬀerence in the morning 
home diastolic blood pressure levels between the two 
groups after treatment.  P values were calculated by 
Mann-Whitneyʼs U-test between both groups in panel 
A and B.  P values were calculated by unpaired t-test 
between both groups in panel C.
ARBs.  Evidence from clinical studies also suggests 
that sustainable inhibition of the RAS at the tissue 
level,  as provided by high-dose monotherapy with an 
ARB,  might aﬀord improved cardiovascular protec-
tion beyond that conferred by a reduction of blood 
pressure [12].  High-dose ARB therapy has been 
shown to have a renoprotective eﬀect in hypertensive 
patients with diabetic nephropathy or non-diabetic 
proteinuric nephropathy,  and this eﬀect has been 
attributed to a decrease in the urine albumin creati-
nine ratio (UACR) [13,  20].  Although several studies 
have reported that blood pressure was signiﬁcantly 
reduced by a high-dose ARB in uncontrolled hyperten-
sive patients who had been receiving an ordinal dosage 
of ARB,  the magnitude of blood pressure reduction by 
the high-dose ARB was less than twice that by the 
ordinal dosage of ARB [13].  In addition,  clinical 
studies examining the eﬃcacy of high-dose ARB for 
morning hypertension are sparse.  This is why high-
dose ARB therapy was an arm in this study.  On the 
other hand,  the eﬃcacy of ARB/thiazide combination 
therapy in the treatment of hypertension has been 
described in several large and small studies [11,  
21-25].  However,  few studies have compared blood 
pressure-lowering eﬀect between ARB/thiazide com-
bination therapy and high-dose ARB therapy [25].  A 
study reported that there were no signiﬁcant diﬀer-
ences in the changes of OBP after 12 weeks of treat-
ment between combination therapy with 16mg cande-
sartan plus 12.5mg HCTZ and monotherapy with 32 
mg candesartan [27].  Although this result may sup-
port the present study in term of OBP reduction,  
there was no data of MHBP reduction.
　 There have been relatively few reports on inter-
ventions to treat morning hypertension.  A recent 
study showed a greater MHBP reduction by combina-
tion therapy with an ARB plus a thiazide diuretic than 
by combination therapy with an angiotensin-converting 
enzyme inhibitor plus a thiazide diuretic or with a 
calcium channel blocker plus a thiazide diuretic [28].  
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Table 3　 Changes of laboratory data
Losartan/HCTZ group
(n＝18)
High-dose ARB group
(n＝17) P value
Δ Cr (mg/dl) 0.06±0.07 0.00±0.07 0.0393
Δ eGFR (ml/min/1.73m2) －3.8±5.6 －0.0±6.7 0.0849
Δ UA (mg/dl) 0.6±0.7 0.0±0.7 0.0369
Δ K (mEq/l) －0.2±0.3 －0.1±0.4 0.4615
Δ HbA1c (%) －0.1±0.4 0.1±0.2 0.9723
Δ LDL-Cho (mg/dl) －1±16 －9±22 0.2826
Δ HDL-Cho (mg/dl) －1±9 1±9 0.5644
Δ TG (mg/dl) 16±69 8±81 0.7312
Δ indicates the value after treatment minus the value at baseline.
Cr,  creatinine; eGFR,  estimated glomerular ﬁltration rate; K,  potassium; UA,  uric acid; HbA1c,  hemoglobin A1c; LDL-Cho,  low density 
lipoprotein cholesterol; HDL-Cho,  high density lipoprotein cholesterol; TG,  triglyceride.
P values were analyzed using Studentʼs t-test or Mann-Whitneyʼs U-test,  where appropriate.
Table 4　 Adverse events
Losartan/HCTZ group
(n＝26)
High-dose ARB group
(n＝22) P value
Brain hemorrhage 1 (4%) 0 (0%) 1.000
Hypotension 1 (4%) 1 (5%) 1.000
Headache 1 (4%) 0 (0%) 1.000
Chest discomfort 1 (4%) 0 (0%) 1.000
Syncope 0 (0%) 1 (5%) 0.4583
Eczema 2 (8%) 0 (0%) 0.4929
P values were analyzed using Fisherʼs exact probability test.
Moreover,  there was only one study compared combi-
nation therapy with an ARB plus a low-dose thiazide 
diuretic to high-dose ARB therapy in treatment of 
patients with morning hypertension other than the 
present study [29].  The previous study found that 
combination therapy with valsartan plus trichlorme-
thiazide reduced not only a reduction of MHBP but 
also brachial-ankle pulse velocity signiﬁcantly more 
than high-dose valsartan therapy.  However,  the cur-
rent study showed signiﬁcant diﬀerences in reduction 
of both systolic and diastolic MHBP between losar-
tan/HCTZ combination therapy and high-dose ARB 
therapy after 3 months of treatment.  Several explana-
tions were considered for the diﬀerent results.  First,  
the patients in the current study were recruited using 
the criteria of morning hypertension deﬁned only as a 
systolic MHBP level of 135mmHg or over.  The pre-
vious study recruited patients using the criteria of 
morning hypertension deﬁned as a systolic MHBP of 
140mmHg or over and bed-time systolic blood pres-
sure under 135mmHg.  Second,  the former study 
enrolled only male patients,  whereas the patients were 
enrolled irrespective of gender in the current study.  
Third,  patients in the former study had been treated 
with only valsartan 80mg once a day,  whereas patients 
in the current study had been treated with any kind of 
ARB with the ordinal dosage.  Fourth,  the former 
study administered 80mg valsartan plus 1mg trichlo-
rmethiazide or 160mg valsartan,  whereas 50mg 
losartan plus 12.5mg HCTZ or the maximum dose of 
the previously described ARB was administered in the 
current study.  Finally,  while the blood pressure 
reduction after treatment was evaluated after 6 
months in the previous study,  it was done after 3 
months in the current study.  Although the blood pres-
sure level after 3 months in the previous study was not 
shown,  we presumed that the eﬃcacy of ARBs on 
MHBP reduction might be developed after 6 months 
of treatment rather than after 3 months,  especially 
when increasing the dosage of the ARB to the maxi-
mum dosage.  Further studies are needed in order to 
clarify this hypothesis.
　 MHBP was decreased gradually during the treat-
ment period in both the Losartan/HCTZ group and the 
High-dose ARB group in the current study.  Although 
there was a signiﬁcant diﬀerence in the systolic 
MHBP level but not in the diastolic MHBP level 
between the 2 groups,  the decreases of both systolic 
and diastolic MHBP in the Losartan/HCTZ group 
were signiﬁcantly greater than those in the High-dose 
ARB group.  This discrepancy in diastolic MHBP 
might have been due to the inclusion criteria in this 
study.  Patients were recruited regardless of their 
diastolic MHBP levels,  thus it was likely that the 
change of the diastolic MHBP level tended to be 
greater.  On the other hand,  the OBP decreased 
similarly in both groups,  and therefore there was no 
signiﬁcant diﬀerence in either the achieved OBP lev-
els or the reduction of OBP between the 2 groups.  
The change of OBP by each treatment was smaller 
than estimated because the OBP of around 140/80 
mmHg at baseline was not high.  In general,  the mag-
nitude of blood pressure reduction was associated with 
the baseline blood pressure level [27],  which might 
explain the results.
　 The achievement of the target blood pressure level 
is a clinically important issue in the treatment of 
hypertension.  The target blood pressure level was 
achieved in only 40ｵ to 50ｵ of hypertensive patients 
who took a single antihypertensive agent [30].  The 
achievement ratio of systolic MHBP under 135mmHg 
in the Losartan/HCTZ group was 72ｵ in the current 
study,  whereas that in the High-dose ARB group was 
35ｵ.  This result suggested that ARB/thiazide com-
bination therapy might achieve a pronounced response 
exceeding that to high-dose ARB therapy in the treat-
ment of uncontrolled morning hypertension.
　 The importance of morning hypertension has been 
reported in several studies.  Morning hypertension is 
related to left ventricular hypertrophy [31-33],  
carotid intima-media thickness [34],  brachial-ankle 
pulse wave velocity [35],  UACR [36],  silent brain 
infarction [37] and cardiovascular events [14-17].  
Furthermore,  several studies have reported that a 
reduction of morning blood pressure led to a reduction 
of UACR in hypertensive patients [36,  38].  It has 
not been elucidated yet whether the attenuation of 
morning hypertension could contribute to beneﬁcial 
eﬀects on morbidity and mortality.  A study demon-
strated a signiﬁcant reduction in cardiovascular events 
and mortality with bed time administration of antihy-
pertensive agents in comparison to morning treatment 
in patients with type 2 diabetes mellitus [16].  
However,  the morning blood pressure at baseline in 
that study was relatively low,  and thus this case could 
not be considered to be an intervention for morning 
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hypertension.  An interim analysis of the HOMED-BP 
(Hypertension Objective treatment based on Measure-
ment by Electrical Devices of Blood Pressure) study,  
a randomized controlled trial to determine the optimal 
target of MHBP,  is expected to show whether the 
reduction of morning hypertension contributes to the 
improvement of mortality and morbidity in hyperten-
sive patients [39].
　 Losartan/HCTZ is thought to be superior in the 
suppression of hyperuricemia in comparison to combi-
nation therapy containing other ARBs,  because 
losartan is able to inhibit urate/anion transport in 
brush-border cells of the renal proximal tubules [40,  
41].  A recent report showed that the eﬀect of 50mg 
losartan on renal excretion of urate was signiﬁcantly 
greater than that of 8mg candesartan in hypertensive 
patients [42].  Moreover,  the lack of a uricosuric 
response to losartan in patients harboring the mutant 
URAT1 gene demonstrated the contribution of URAT1 
to the uricosuric action of losartan in humans.  The 
current study found that the change of UA in the 
Losartan/HCTZ group was signiﬁcantly higher than 
that in the High-dose ARB group.  Furthermore,  3 
patients were newly diagnosed with hyperuricemia in 
the Losartan/HCTZ group whereas none of patients 
were diagnosed with hyperuricemia in the High-dose 
ARB group.  However,  the occurrence of hyperurice-
mia in the Losartan/HCTZ group was as mild as 
estimated.  Although the side eﬀects of thiazide 
diuretics have been considered frequent and problem-
atic,  they are infrequent and trivial following the 
administration of a low dosage.  Furthermore,  thiazide 
diuretics have an advantage because they are less 
expensive than other antihypertensive agents.
　 As to the mechanism underlying the diﬀerence in 
MHBP reduction between therapies,  it may have 
involved a diﬀerence in salt sensitivity between patients 
undergoing the two treatments.  It is well recognized 
that RAS inhibitors enhance sodium sensitivity.  It is 
also well known that the BP-lowering eﬀect of RAS 
inhibitors is blunted by a high sodium diet.  Therefore,  
diuretics enhance the eﬃcacy of RAS inhibitors on BP 
reduction because of their natriuretic action.  Since 
elevations in MHBP are associated with nocturnal 
hypertension,  morning hypertension may be common in 
patients with high sodium sensitivity who have a high 
sodium intake.  It has been reported that HCTZ 
reduced the nocturnal BP of hypertensive patients 
with a change of non-dipper to dipper status [43].  In 
our study,  since all participants received an ordinal 
dosage of ARB,  their salt sensitivity might have been 
enhanced.
　 Several limitations need to be recognized in inter-
preting the results of this study.  First,  this study 
enrolled a small number of participants,  and therefore 
it failed to show a signiﬁcant diﬀerence on diastolic 
MHBP levels between the 2 groups.  Second,  the dos-
age of previously prescribed ARBs was increased to 
the maximum dosage in the High-dose ARB group.  
There may be diﬀerences among the individual ARBs 
regarding the blood pressure-lowering eﬀect in hyper-
tensive patients,  and such diﬀerences might have 
aﬀected the results.  Indeed,  3 patients (losartan),  4 
patients (candesartan),  1 patient (valsartan),  5 
patients (telmisartan),  and 4 patients (olmesartan) 
were assigned to the High-dose ARB group.  However,  
there were no signiﬁcant diﬀerences among ARBs 
regarding the decrease of systolic and diastolic 
MHBP (data not shown).  Third,  the duration of our 
study was short,  so that morbidity and mortality could 
not be evaluated.  Finally,  there was no ambulatory 
blood pressure monitoring and evening home blood 
pressure data in this cohort.
　 In conclusion,  the present study demonstrated the 
eﬃcacy of the combination therapy with losartan/
HCTZ compared to high-dose ARB therapy for the 
treatment of MHBP.  A combination therapy of ARB/
thiazide may be recommended rather than increasing 
the dosage of ARB,  when treatment of morning 
hypertension by ARB monotherapy is insuﬃcient to 
achieve the target blood pressure level.
Appendix
Participants and participating centers
　 Takanobu Nakajima,  Kato & Namiki-dori Hospital; Hiroshi Hirata,  
Masaki Aono,  Akebono Clinic; Eriko Katayama,  Toshio Ogura,  Sato 
Hospital; Toshiyuki Shinji,  Konandai Clinic; Masashi Muguruma;  
Okayama Memorial Hospital; Taro Sugimoto,  Sugimoto Clinic; Tsutomu 
Tomono,  Tomono Naika Clinic; Tadaaki Fujiwara,  Okayama Hakuai-kai 
Hospital; Hiromichi Kameyama,  Mimasaka Central Hospital; Hitomi 
Kataoka-Usui,  Okayama University Hospital.
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